Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial.

Date publication

février 2026

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Pr WESTEEL Virginie , Dr FAVIER Laure , Pr MASCAUX Céline

Tous les auteurs :
Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41690366

Résumé

Optimal first-line immunotherapy duration in metastatic non-small-cell-lung cancer (mNSCLC) with controlled disease remains unclear. We evaluated 6-month nivolumab-ipilimumab (IO) in patients with disease control (DC).

Référence

J Thorac Oncol. 2026 02 12;:103609